Antisense inhibition of bcl-6 expression

Details Antisense inhibition of bcl-6 expression Antisense inhibition of bcl-6 expression

1999-10-15

2000-10-31

Elliott, George C.

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of regulating cell metabolism or physiology

435375, 435325, 435366, 435 6, 435 911, 536 231, 536 2431, 536 2433, 536 245, C12Q 168, C07H 2104, C12N 1500

Patent

active

061401250

ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of bc1-6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bc1-6. Methods of using these compounds for modulation of bc1-6 expression and for treatment of diseases associated with expression of bc1-6 are provided.

REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5882858 (1999-03-01), Dalla-Favera et al.
Kerckaert et al., LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas, Nat. Genet., 1993, 5:66-70.
Nakamura et al., Internal DNA deletion within the BCL-6 gene on untranslocated chromosome in non-Hodgkin's lymphoma with 3q27 abnormality, Leukemia, 1996, 10:658-661.
Niu et al., Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor, Genes Dev., 1998, 12:1953-1961.
Ohno et al., Heterogeneity in B-cell neoplasms associated with rearrangement of the LAZ3 gene on chromosome band 3q27, Jpn. J. Cancer Res., 1994, 85:592-600.
Otsuki et al., Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences, Blood, 1995, 85:2877-2884.
Seyfert et al., Transcriptional repression by the proto-oncogene BCL-6, Oncogene, 1996, 12:2331-2342.
Yamochi et al., Adenovirus-mediated high expression of BCL-6 in CV-1 cells induces apoptotic cell death accompanied by down-regulation of BCL-2 and BCL-XL, Oncogene, 1999, 18:487-494.
Ye et al., Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma, Science, 1993, 262:747-750.
Ye et al., Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma, Cancer Res., 1993, 53:2732-2735.
Dhordain et al., The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo, Oncogene, 1995, 11:2689-2697.
Dhordain et al., Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein, Proc. Natl. Acad. Sci. U. S. A., 1997, 94:10762-10767.
Dhordain et al., The LAZ3 (BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression, Nucleic Acids Res., 1998, 26:4645-4651.
Flenghi et al., Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region, Am. J. Pathol., 1996, 148:1543-1555.
Flenghi et al., A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. Am. J. Pathol., 1995, 147:405-411.
Gaidano et al., Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis, Genes, Chromosomes Cancer, 1999, 24:16-23.
Gaidano et al., Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype, Blood, 1994, 84:397-402.
Ichinohasama et al., A recurrent nonrandom translocation (3;7) (q27;p12) associated with BCL-6 gene rearrangement in B-cell diffuse large cell lymphoma, Cancer Genet. Cytogenet., 1998, 104:19-27.
Kanazawa et al., Expression of bcl-6 protein in normal skin and epidermal neoplasms, Pathol. Int., 1997, 47:600-607.
Albagli et al., Multiple domains participate in distance-independent LAZ3/BCL6-mediated transcriptional repression, Biochem. Biophys. Res. Commun., 1996, 220:911-915.
Baron et al., BCL6 encodes a sequence-specific DNA-binding protein, Genes, Chromosomes Cancer, 1995, 13:221-224.
Bastard et al., LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients, Blood, 1994, 83:2423-2427.
Berger et al., Presence of three recurrent chromosomal reaarrangements, t (2;3) (p12;q37), del (8) (q24), and t (14;18), in an acute lymphoblastic leukemia, Cancer Genet. Cytogenet., 1996, 86:76-79.
Bernardin et al., Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation, Oncogene, 1997, 14:849-855.
Capello et al., Point mutations of the BCL-6 gene in Burkitt's lymphoma, Br. J. Haematol., 1997, 99:168-170.
Daudignon et al., Four cases of follicular lymphoma with t (14;18) (q32;q21) and t (3;4) (q27;p13) with LAZ3 (BCL6) rearrangement, Cancer Genet. Cytogenet., 1999, 111:157-160.
Delecluse et al., Bc16/Laz3 rearrangements in post-transplant lymphoproliferative disorders, Br. J. Haematol., 1995, 91:101-103.
Deweindt et al., The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain, Cell Growth Differ., 1995, 6:1495-1503.
Crooke, "Antisense Research and Application"; Springer, New York; pp. 1-50, Oct. 1996.
Agrawal, TIBTech, vol. 14, pp. 376-387, Oct. 1996.
Branch, TIBS23, pp. 45-50, Feb. 1998.
James, Antiviral Chemistry and Chemotherapy, 2 (4), pp. 191-214, 1991.
Milner et al., Nature Biotechnology, vol. 15, pp. 537-541, Jun. 1997.

Affiliated with

Also associated with

Rating

Antisense inhibition of bcl-6 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense inhibition of bcl-6 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense inhibition of bcl-6 expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2050198